Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04787445 · ClinicalTrials.gov registry record
Effects of Pulmonary Hypertension Therapy in Atypical Pulmonary Arterial Hypertension
A clinical trial, sponsored by Mayo Clinic.
- Completed
- Registry status
- 19
- Enrollment target
NCT04787445: Completed study, sponsored by Mayo Clinic.
NCT04787445 is a clinical trial that has completed, run by Mayo Clinic. The registered enrollment target is 19 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04787445 has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 19 participants
- Enrollment target
Study Summary
The purpose of this study is to characterize the clinical and hemodynamic response of Pulmonary Arterial Hypertension (PAH) therapy in patients with atypical PAH and risk factors for left heart disease.
Primary Outcome
Pulmonary arterial wedge pressure \>25 mmHg during exercise cardiac catheterization will indicate occult left heart disease.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2021-03-11 |
| Est. Completion | 2023-11-21 |
What the finished NCT04787445 record still lists
NCT04787445 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 19 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT04787445 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04787445 about?
NCT04787445 is a clinical study titled "Effects of Pulmonary Hypertension Therapy in Atypical Pulmonary Arterial Hypertension". The purpose of this study is to characterize the clinical and hemodynamic response of Pulmonary Arterial Hypertension (PAH) therapy in patients with atypical PAH and risk factors for left heart disease.
What is the current status of trial NCT04787445?
This trial is currently completed. The enrollment target is 19 participants. The study started on 2021-03-11. Estimated completion is 2023-11-21.
Who is sponsoring clinical trial NCT04787445?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI